Neuropsychology in schizophrenia: An update

Current Opinion in Psychiatry

Volumn 16, Issue 2, 2003, Pages 149-155

  Hoff, Anne L ^a,b   Kremen, William S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cognitive disorders; Neuropsychology; Schizophrenia

Indexed keywords

CYCLOSERINE; CYPROHEPTADINE; DONEPEZIL; GUANFACINE; HALOPERIDOL; ICOSAPENTAENOIC ACID ETHYL ESTER; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

AGING; ATTENTION DEFICIT DISORDER; BRAIN FUNCTION; BRAIN REGION; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; DISEASE COURSE; FAMILY STUDY; HUMAN; MEMORY DISORDER; META ANALYSIS; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROBLEM SOLVING; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SOCIAL BEHAVIOR;

EID: 0037336805     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200303000-00003     Document Type: Review

References (56)

1. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr Clin North Am 1993; 16:295-312.
2. Hoff AL. Neuropsychological function in schizophrenia. In Shriqui CL, Nasrallah HA, editors. Contemporary issues in the treatment of schizophrenia. Washington, DC: American Psychiatric Press; 1995. pp. 187-208.
3. Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry 1991; 48:618-624.
4. Cornblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophrenia Bull 1994; 20:31-46.
5. Liu SK, Chiu C-H, Chang C-J, et al. Deficits in sustained attention in schizophrenia and affective disorders: stable versus state-department markers. Am J Psychiatyr 2002; 159:975-982. This paper demonstrates that attentional deficits are most marked in patients with schizophrenia compared with other groups with psychosis.
6. Wiedi K, Wienobst J, Schottke HH, et al. Attentional characteristics of schizophrenia patients differing in learning proficiency on the Wisconsin Card Sorting Test. Schizophrenia Bull 2001; 27:687-696. This paper defines subgroups of patients based on higher-order problem-solving ability and explores the contribution of attentional function to these abilities.
7. Goldstein K. Functional disturbances in brain damage. In: Arleti S, editor. American handbook of psychiatry. New York: Basic Books; 1959. pp. 770-794.
8. Johnson-Selfridge M, Zalewski C. Moderator variables of executive functioning in schizophrenia: meta-analytic findings. Schizophrenia Bull 2001; 2:305-316.
9. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiolog Behav 1984; 32:489-502.
10. Good KP, Martzke JS, Milliken HI, et al. Unirhinal olfactory identificaiton deficits in young male patients with schizophrenia and related disorders: association with impaired memory function. Schizophrenia Res 2002; 56:211-223.
11. Goldman-Rakic PS. Circuitry of primate prefrontal cortex and regulation of behavior by representational memory. In: Plum F, Mountcastle V, editors. Handbook of physiology - the nervous system, vol. V: Higher functions of the brain. Bethesda, MD: American Physiological Society; 1987. pp. 373-417.
12. Gooding DC, Tallent KA. Spatial working memory performance in patients with schizoaffective psychosis versus schizophrenia: a tale of two disorders? Schizophrenia Res 2002; 53:209-218.
13. Seidman LJ, Kremen WS, Koren D, et al. A comparative profile analysis of neuropsychological function in schizophrenia and bipolar psychoses. Schizophrenia Res 2002; 53:31-44.
14. Hoff AL, Sakuma M, Wieneke M, et al. A longitudinal neuropsychological follow-up study of patients with first episode schizophrenia. Am J Psychiatry 1999; 156:1336-1341.
15. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000; 157:549-559.
16. Schuepbach D, Keshavan MS, Kmiec JA, Sweeney JA. Negative symptom resolution and improvements in specific cognitive deficits after acute treatment in first-episode schizophrenia. Schizophrenia Res 2002; 53:249-261.
17. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994; 51:124-131.
18. Heaton RK, Gladsjo JA, Palmer BW, et al. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 2001; 58:24-32.
19. Grawe RW, Levander S. Neuropsychological impairments in patients with schizophrenia: stability and prediction of outcome. Acta Psychiatr Scand 2001; 104:60-64.
20. Fuller R, Nopoulos P, Arndt S, et al. Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry 2002; 159:1183-1189. This paper evaluates premorbid cognitive functions in individuals who later develop schizophrenia. The data suggest that not only are achievement scores lower in pre-schizophrenia patients, but that these scores drop rather precipitously from grades 8 to 11, a time during which synaptic pruning occurs.
21. Harvey PD. Cognitive functioning in late-life schizophrenia: its importance and implications for overall outcome. J Clin Psychiatry 1999; 60:10-16.
22. McBride T, Moberg PJ, Arnold SE, et al. Neuropsychological functioning in elderly patients with schizophrenia and Alzheimer's disease. Schizophrenia Res 2002; 55:217-227. This paper demonstrates the degree of cognitive impairment in schizophrenia patients compared with Alzheimer's patients. It is surprising that a measure of object naming was performed worse in the schizophrenia group. One might speculate that the left hemisphere may be selectively damaged in chronically ill schizophrenia patients.
23. Egan MF, Goldberg TE, Gscheidle T, et al. Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biol Psychiatry 2001; 50:98-107.
24. Dollfus S, Lombardo C, Benali K, et al. Executive/attentional cognitive functions in schizophrenic patients and their parents: a preliminary study. Schizophrenia Res 2002; 53:93-99.
25. Wolf LE, Cornblatt BA, Roberts SA, et al. Wisconsin Card Sorting deficits in the offspring of schizophrenics in the New York high risk project. Schizophrenia Res 2002; 57:173-182.
26. Gilvarry CM, Russell A, Hemsley D, Murray RM. Neuropsychological performance and spectrum personality traits in the relatives of patients with schizophrenia and affective psychosis. Psychiatry Res 2001; 101:89-100.
27. Kremen WS, Hoff AL. Neurocognitive deficits in the biological relatives of individuals with schizophrenia. In: Stone W, Faraone S, Tsuang M, editors. Early clinical intervention and prevention in schizophrenia. Totowa, NJ: Humana Press, Inc.; 2002. (in press).
28. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Mer genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001; 98:6917-6922. This paper takes the first step in identifying a cognitive phenotypic marker associated with a specific genotype.
29. Bilder RM, Volavka J, Czobor P, et al. Neurocognitive correlates of the COMT Val (158) Met polymorphism in chronic schizophrenia. Biol Psychiatry 2002; 52:701-704. This paper confirms findings from the paper by Egan et al. [28••].
30. Szeszko PR, Strous RD, Goldman RS, et al. Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia. Am J Psychiatry 2002; 159:217-226.
31. Honey GD, Bullmore ET, Sharma T. De-coupling of cognitive performance and cerebral functional response during working memory in schizophrenia. Schizophrenia Res 2002; 53:45-56.
32. Barch DM, Carter CS, Braver TS, et al. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch Gen Psychiatry 2001; 58:280-288. Using a functional MRI paradigm measuring working memory, this study found selective activation in the dorsolateral prefrontal cortex in controls and first-episode schizophrenia patients.
33. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9:357-381.
34. Seidman LJ, Faraone SV, Goldstein JM, et al. Left hippocampal volume as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric of nonpsychotic first-degree relatives. Arch Gen Psychiatry 2002; 59:839-849.
35. Green MG, Kern RS, Braff DL, Mintz JM. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? Schizophrenia Bull 2000; 26:119-136.
36. Dickinson D, Coursey RD. Independence and overlap among neurocognitive correlates of community functioning in schizophrenia. Schizophrenia Res 2002; 56:161-170.
37. Wilder-Willis KE, Shear PK, Steffen JJ, Borkin J. The relationship between cognitive dysfunction and coping abilities in schizophrenia. Schizophrenia Res 2002; 55:259-267.
38. Brekke JS, Kohrt B, Green MF, Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. Schizophrenia Bull 2001; 27:697-708.
39. Smith TE, Hull JW, Huppert JD, Silverstein SM. Recovery from psychosis in schizophrenia and schizoaffective disorder: symptoms and neurocognitive rate-limiters for the development of social behavior skills. Schizophrenia Res 2002; 55:229-237.
40. Addington J, Addington D, Gasbarre L. Neurocognitive and social functioning in schizophrenia and other diagnoses [Letter to the editor]. Schizophrenia Res 2001; 48:361-370.
41. Bell MD, Bryson G. Work rehabilitation in schizophrenia: does cognitive impairment limit improvement? Schizophrenia Bull 2001; 27:269-279.
42. Gold JM, Goldberg RW, McNary SW, et al. Cognitive correlates of job tenure among patients with severe mental illness. Am J Psychiatry 2002; 159:1395-1402.
43. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159:18-1028. This study is a double-blind study with relatively large sample sizes evaluating cognitive improvement in patients assigned to these commonly used neuroleptic agents. Patients taking risperidone and olanzapine were superior to the haloperidol group on a global cognitive scale. Risperidone was significantly better on measures of memory than other neuroleptic agents.
44. Potkin SG, Fleming K, Jin Y, Gulaekaram B, Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin Psychpharmacol 2001; 21:479-483.
45. Green MF, Marder SR, Glynn SM, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 2002; 51:972-978.
46. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321:1372-1376.
47. Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001; 158:2071-2074.
48. Evins AE, Amico E, Posever TA, et al. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophrenia Res 2002; 56:19-23.
49. Friedman JI, Adler DN, Howanitz E, et al. A double blind placebo controlled trial of donepezil adjuctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 2002; 51:349-357.
50. Friedman JI, Adler DN, Temporini HD, et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 2001; 25:402-409.
51. Sumiyoshi T, Matsui M, Nohara S, et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 2001; 158:1722-1725.
52. Chaudhry IB, Soni SD, Hellewell JSE, Deakin JFW. Effects of the 5HT antagonist cyproheptadine of neuropsychological function in chronic schizophrenia. Schizophrenia Res 2002; 53:17-24.
53. Kurtz MM, Moberg PJ, Gur RC, Gur RE. Approaches to cognitive remediation of neuropsychological deficits in schizophrenia: a review and meta-analysis. Neuropsychol Rev 2001; 11:197-210.
54. Medalia A, Revheim N, Casey M. Remediation of problem-solving skills in schizophrenia: evidence of a persistent effect. Schizophrenia Res 2002; 57:165-171. This well-designed study demonstrated that specific problem-solving training is related to better clinical outcome measured on the Independent Living Scales in patients with schizophrenia.
55. Loeb PA. Independent living scales manual. San Antonio, Texas: Psychological Corporation; 1996.
56. Brown AS. New perspectives on the neurodevelopmental hypothesis of schizophrenia. Psychiatr Ann 1999; 29:128-130.